cancer

starBase v2.0 logoStarBase has been updated to explore Pan-Cancer pattern of lncRNAs, miRNAs, RNA-binding proteins (RBP) and their regulatory networks (ceRNA, coexpression) by mining expression profiles of miRNAs, lncRNAs and mRNAs across 14 cancer types (>6000 samples) from The Cancer Genome Atlas (TCGA) Data Portal (all data available without limitations).
StarBase provides the following Pan-Cancer Analysis Services:
  1. starBase constructed Pan-Cancer expression profiles of lncRNAs, miRNAs from TCGA RNA-Seq and miRNA-Seq data.
  2. starBase generated Pan-Cancer networks of CLIP-Seq experimentally supported miRNA-lncRNA and miRNA-mRNA interactions.
  3. starBase identified Pan-Cancer ceRNA networks involving lncRNAs and mRNAs by analyzing >6000 tumor and normal samples and [click to continue…]

{ 0 comments }

Mirna Broadens Rights to Its Lead Cancer Therapeutic Candidate MRX34

Marina Biotech LogoBOSTON, MA and AUSTIN, TX–(Marketwired – Jan 2, 2014) – Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, and Mirna Therapeutics, Inc. (Mirna), a privately-held biotechnology company pioneering microRNA (miRNA) replacement therapy for cancer, announced today that they have amended their license agreement regarding the development and commercialization of microRNA-based therapeutics utilizing Mirna’s proprietary microRNAs and Marina Biotech’s novel SMARTICLES liposomal delivery technology. Under terms of the amendment, Mirna paid certain pre-payments to Marina Biotech and now has additional rights to its lead program, MRX34, currently in Phase 1 clinical development for patients with unresectable primary liver cancer or metastatic cancer with liver involvement. In addition, under the terms of the license agreement, Mirna has optioned exclusivity on several additional miRNA targets. Further terms of the Agreement were not disclosed.

“Mirna and Marina Biotech have enjoyed a successful, durable collaboration by leveraging the systemic delivery of our proprietary, double-stranded, miRNA mimics with the SMARTICLES delivery technology,” said Paul Lammers, President and CEO of Mirna Therapeutics. “Amendment of the license agreement strengthens [click to continue…]

{ 0 comments }

Expands the Company’s Patent Portfolio in Oncology Therapeutics

Rosetta Genomics LogoPRINCETON, NJ and REHOVOT, ISRAEL–(Marketwired – Nov 7, 2013) – Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces receipt of a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) related to U.S. Patent Application No. 13/481,105 titled “Targeting microRNAs for the Treatment of Liver Cancer.”

This allowance is for a therapeutic patent that protects a method for treating hepatocellular carcinoma (HCC), or liver cancer, and covers the administration of a compound comprising a modified oligonucleotide that is an anti-miR-222. In addition, various modifications of the nucleotide are claimed. There is an additional claim which refers to the reduction of the levels of serum alpha-fetoprotein or serum des-gamma-carboxyprothrombin in the subject to be treated.

“HCC is the fifth most common cancer in the world and the third leading cause of cancer deaths. Because standard chemotherapy usually has no beneficial outcome on HCC patients, there is significant need for new therapeutic modalities and novel therapeutic [click to continue…]

{ 0 comments }

Demonstrating Increased Demand for the Rosetta Cancer Origin Test

PRINCETON, NJ and REHOVOT, ISRAEL–(Marketwired – Sep 10, 2013) – Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, today reports financial results for the six months ended June 30, 2013.

Commercial highlights for the first half of 2013 and recent weeks include:

  • Enhanced awareness of, and demand generation for, the Rosetta Cancer Origin Test™ resulting in a four-fold increase in revenues compared with the same period a year ago
  • Expanded the U.S. commercial footprint from five sales territories to 12, and increased the direct sales force from four representatives to 10; brought sales professionals in house from contract sales organization
  • Received the final revised Local Coverage Determination for Biomarkers in Oncology from the designated Medicare Administrative Contractor for the Company’s microRNA-based diagnostic assays, which included [click to continue…]

{ 0 comments }

mirna bladder cancer publication

NOTE: hsa-miR-29c* mentioned in the following paper is the retired name for what is now hsa-miR-29c-5p: http://www.mirbase.org/cgi-bin/mature.pl?mature_acc=MIMAT0004673

PHILADELPHIA and REHOVOT, Israel, Feb. 7, 2013 /PRNewswire/ — Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that data from a study demonstrating the ability of microRNA expression to serve as a biomarker to predict the progression of bladder urothelial carcinoma were published online in the British Journal of Urology International, in an article entitled, “Predicting progression of bladder urothelial carcinoma using microRNA expression.” The article can be accessed online at http://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2012.11748.x/abstract and is expected to be published in the print edition of the British Journal of Urology International. 

In the study, formalin-fixed, paraffin-embedded samples of 108 non-muscle invasive (“NMI”) bladder carcinomas, and 29 muscle invasive tumors, were collected and highly specific microRNA expression levels were measured by Rosetta Genomics’ microarray technology. Using micro-dissection, specific tumor microRNAs were chosen to be included in the study in order to avoid background contamination derived from surrounding tissue.  The study found that the expression level of one microRNA, miR-29c*, was significantly under-expressed in tumors that progressed and could be used to stratify bladder cancer patients into risk groups.

The study showed that significantly higher expression of miR-29c* was detected in NMI bladder tumors that did not progress compared with lesions that did progress. The lower expression of miR-29c* in patients that later progressed was similar to the expression levels seen in patients with muscle invasive disease.

Prediction of recurrence and progression is currently based upon clinical and pathological factors such as: tumor grade, tumor stage, number of lesions, tumor size, prior recurrence rate and presence of concomitant carcinoma in-situ (“CIS”).  These factors are not [click to continue…]

{ 0 comments }

Rosetta Genomics Reports Study Comparing microRNA Profiles of Cancer of Unknown Primary and Metastases of Known Primary Tumors

January 9, 2013

PHILADELPHIA and REHOVOT, Israel, Jan. 9, 2013 /PRNewswire/ — Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that data from a study assessing the differences between cancer of unknown primary (CUP) and metastatic solid tumors of known primary metastases (KPM) by profiling microRNA expression were recently published […]

Read the full article →

Rosetta Genomics and Precision Therapeutics Announce U.S. Commercial Launch of miRview® mets2

October 2, 2012

Medicare-Covered Assay Accurately Identifies Tumor of Origin in Cancer of Unknown Primary PHILADELPHIA, REHOVOT, Israel, and PITTSBURGH, Oct. 2, 2012 /PRNewswire/ — Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, and Precision Therapeutics, Inc. (PTI), a life science company known for its expertise in the science of personalizing cancer […]

Read the full article →

miREC: Database of miRNAs involved in endometrial cancer

September 19, 2012

The miREC database (miRNAs involved in Endometrial Cancer) combines published data about miRNAs and genes deregulated in endometrial cancer, as well as target-regulator relationships between these genes and miRNAs. All information has been extracted from published literature and entries are supplemented by reference citations. The miREC database was launched in February 2011  by researchers at […]

Read the full article →

3rd International Symposium on Cancer, microRNAs, and other non-coding RNAs

September 10, 2012

Very last minute – but if you are near London and don’t have any plans for Wednesday this might be right event for you: The third international symposium on Cancer, microRNAs and other non-coding RNAs will highlight the function and regulation of non-coding RNAs during oncogenesis. The symposium will cover a wide range of themes, […]

Read the full article →

Upcoming Cancer microRNA Webinar

July 9, 2012

Title: Recent Work & Current Methods in Cancer microRNA Research – The 2nd in a series of microRNA Webinars presented by LC Sciences Date: Wed 7/11/12 Please register for the webinar by selecting the presentation time that is most convenient for your timezone. North America  – 1:00 Central Daylight Time Europe – 1:00 PM Greenwich […]

Read the full article →